Adbiotech Co. Ltd. (179530) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Adbiotech Co. Ltd. stock KRW 323, price KRW 1,346, that is 76.0% below the price, quality 25 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
57‑month range 1,343 KRW – 9,240 KRW · fair‑value band 241.15 KRW – 482.28 KRW · the 1,346 KRW price screens above the 323.13 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Adbiotech Co. in your weekly email
Every Wednesday you see whether Adbiotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods.
Show moreShow less
ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.
Stock analysis
Adbiotech Co. Ltd. (179530) currently trades at 1,346 KRW, while our model-based Fair Value estimate is 323.13 KRW, 76% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 89/100, which puts the data coverage at low.
Scenario range: 241.15 KRW (bear) to 482.28 KRW (bull), the price of 1,346 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Adbiotech Co. Ltd. reported revenue of 12.9B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +2.2%/yr. Reported net income was −3.3B KRW in FY2025.
Key figures
Market cap 36.3B KRW (≈ $26.8M) Micro · P/S ratio 4.14 · EPS (TTM) −130.92 KRW · Net margin −25.6% · Return on equity −23.6% · Return on assets (EBIT) −15.5% (5-year average) · Operating margin −66.7% · Revenue (TTM) 12.6B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).
What moves the price
The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −76%, 179530 screens richer than that median.
Fair Value models
Bear241.15 KRWFair Value 323.13 KRWBull482.28 KRW
Price 1,346 KRW · Downside -76.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)283.70 KRW380.15 KRW567.39 KRW54
All 1 models by family
Asset-Based
NCAV (Graham)283.70 KRW380.15 KRW567.39 KRW54
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.16/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic)
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’14
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.1% (2020) → −27.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−76.0% · Bottom 25%
Profitability
Return on assets−6.8% · Above median
Net margin (12 months)−28.1% · Bottom 25%
Operating margin (12 months)−66.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)2.0% · Above median
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.37× · Pricier than median
P/S (12 months)2.89× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)10· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)90· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Adbiotech Co. Ltd. (179530) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 323.13 KRW versus a price of 1,346 KRW, about 76% lower (overvalued).
What is the fair value of 179530?
Our model-based fair value for Adbiotech Co. Ltd. is 323.13 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 1,346 KRW.
What is the quality score of 179530?
Adbiotech Co. Ltd. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Adbiotech Co. Ltd. (179530)?
Our model-based price target is the fair value of 323.13 KRW (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 241.15 KRW, optimistic scenario 482.28 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Adbiotech Co. Ltd. stock forecast for 2026?
Our models put fair value at 323.13 KRW, about 76% lower versus a price of 1,346 KRW (overvalued). Cautious scenario 241.15 KRW, optimistic scenario 482.28 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Adbiotech Co. Ltd. (179530)?
Adbiotech Co. Ltd. reported trailing-twelve-month revenue of about 12.6B KRW (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Adbiotech Co. Ltd. (179530)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Adbiotech Co. Ltd. it is 323.13 KRW per share (as of Nov 4, 2026), against a price of 1,346 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Adbiotech Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 179530 trades above its calculated fair value: price 1,346 KRW, fair value 323.13 KRW, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 179530?
No. The price is what the market pays today (1,346 KRW); the fair value is what the company's own numbers justify (323.13 KRW). For Adbiotech Co. Ltd. the two are 1,023 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Adbiotech Co. Ltd. worth?
The market values Adbiotech Co. Ltd. at about 36.3B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 1,346 KRW; our models calculate a fair value of 323.13 KRW per share.
What do the bullish and bearish scenarios say about 179530?
Our models span a range for Adbiotech Co. Ltd.: cautious scenario 241.15 KRW, base 323.13 KRW, optimistic 482.28 KRW per share (as of Nov 4, 2026, price 1,346 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Adbiotech Co. Ltd. (179530)?
Balance-sheet figures for Adbiotech Co. Ltd. (as of Nov 4, 2026): return on equity −23.6%, debt of 0.20 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 179530 from its 52-week high?
Adbiotech Co. Ltd. trades at 1,346 KRW, about 66% below its 52-week high of 3,945 KRW and at the low of 1,343 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 323.13 KRW is for.
Which stocks are comparable to Adbiotech Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Adbiotech Co. Ltd. stock attractive at the current price?
The data as of Nov 4, 2026: price 1,346 KRW, calculated fair value 323.13 KRW (−76%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 179530 calculated?
We run Adbiotech Co. Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 323.13 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Adbiotech Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Adbiotech Co. Ltd. (179530)?
The closing price on Nov 6, 2026 was 1,346 KRW. Our model-based fair value is 323.13 KRW, about 76% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Adbiotech Co. Ltd. right now?
The price sits above even our optimistic bull case (482.28 KRW). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (241.15 KRW to 482.28 KRW) leaves room in how you read the outcome.
Key figures of Adbiotech Co. Ltd.
How large is the market capitalisation of Adbiotech Co. Ltd. (179530)?
The market capitalisation of Adbiotech Co. Ltd. is 36.3B KRW (≈ $26.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Adbiotech Co. Ltd. (179530)?
The price-to-sales ratio of Adbiotech Co. Ltd. is 4.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Adbiotech Co. Ltd. (179530)?
Earnings per share at Adbiotech Co. Ltd. are −130.92 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Adbiotech Co. Ltd. (179530)?
The net margin of Adbiotech Co. Ltd. is −25.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Adbiotech Co. Ltd. (179530)?
The return on equity (ROE) of Adbiotech Co. Ltd. is −23.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Adbiotech Co. Ltd. (179530)?
On an EBIT basis the return on assets of Adbiotech Co. Ltd. is −15.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Adbiotech Co. Ltd. (179530)?
The operating margin of Adbiotech Co. Ltd. is −66.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Adbiotech Co. Ltd. (179530)?
Revenue at Adbiotech Co. Ltd. is growing +2.0% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Adbiotech Co. Ltd. (179530) generate?
The free cash flow of Adbiotech Co. Ltd. is −1.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Adbiotech Co. Ltd. (179530) carry?
The net debt of Adbiotech Co. Ltd. is 12.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Adbiotech Co. Ltd. in the live analysis
One click puts Adbiotech Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026